Cabazitaxel for the treatment of prostate cancer. - sprookjes - yvandenbroek - TriplyDB

Cabazitaxel for the treatment of prostate cancer.

Cabazitaxel for the treatment of prostate cancer.

http://www.wikidata.org/entity/Q37853193

about

Novel non-AR therapeutic targets in castrate resistant prostate cancer Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.

P2860

Q28383663-F702B858-F881-4F81-8337-4B7E4DDE829D Q39097201-E2DA29E4-03EB-404C-A635-6AA08E1373F0

P2860

Cabazitaxel for the treatment of prostate cancer.

http://www.wikidata.org/entity/Q37853193

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cabazitaxel for the treatment of prostate cancer.

@en

Cabazitaxel for the treatment of prostate cancer.

@nl

type

label

Cabazitaxel for the treatment of prostate cancer.

@en

Cabazitaxel for the treatment of prostate cancer.

@nl

prefLabel

Cabazitaxel for the treatment of prostate cancer.

@en

Cabazitaxel for the treatment of prostate cancer.

@nl

P1433

Q37853193-0375516D-4DFA-4202-A7FB-0BD36DCE5BC4

P1476

Q37853193-5E04345C-2FCB-43AD-883D-0435BBB06487

P2093

Q37853193-1859369B-98C1-4A36-A861-5D5E7BF6BB77

Q37853193-2E087714-055E-4526-97D0-C16A39FAB532

Q37853193-FD961721-0B12-4641-A562-EDDA572C3BEB

P2860

Q37853193-01CCD478-2D7C-414A-A6B9-08373F1FCA30

Q37853193-13F49867-F1AC-48E9-9834-30AF9590D160

Q37853193-1BCE0AD4-F2F2-4B93-B893-3FD88312DA19

Q37853193-1CF14AF1-9867-46DB-BC37-AC1680C12769

Q37853193-1FAA53C7-9231-41D1-B4EC-6D19563130BF

Q37853193-43384D2A-4162-4223-81FA-550319CADAB3

Q37853193-52050B61-1EC5-4679-BEDD-2721978A5ED3

Q37853193-6D0A2728-8373-47D3-9D1E-98287DA14A55

Q37853193-6F92A940-E18B-4DE0-A4E1-10A7115E1BFD

Q37853193-709DF606-5390-41F7-AD31-6CA93FC2F348

P304

Q37853193-2CDFFB50-5702-4088-82B9-C58170CD4964

P31

Q37853193-0B91BCB4-147A-4B62-8416-7E037B041359

P356

Q37853193-C9F0CC36-98D3-484F-A336-47594AB500BE

P407

Q37853193-CBA80F7E-0D9F-4456-BC55-7F771B9476E6

P433

Q37853193-DECEA5FD-A86A-4F8F-A1CC-B86AB4B1C84D

P478

Q37853193-6B15DA1A-E1B9-47FC-8EA3-3A0B5573AF39

P577

Q37853193-E8821AFB-C958-4E86-817F-316A0DF10C95

P698

Q37853193-0BEAF5FB-6F98-4B0B-8169-728A68538D93

P921

Q37853193-4690DF3D-258D-4F68-9684-128F73B18A84

P356

14656566.2011.567268

P1433

Expert Opinion on Pharmacotherapy

P1476

Cabazitaxel for the treatment of prostate cancer.

@en

P2093

Dirk P J Michielsen

http://www.w3.org/2001/XMLSchema#string

Johan G Braeckman

http://www.w3.org/2001/XMLSchema#string

Louis Denis

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Microtubules as a target for anticancer drugs

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines

Estimates of cancer incidence and mortality in Europe in 2008.

Preclinical evaluation of new taxoids.

P304

977-982

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2011.567268

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21406025

http://www.w3.org/2001/XMLSchema#string

P921